Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotine polacrilex is a pharmaceutical formulation in which nicotine is bound to an ion-exchange resin (such as polymethacrylic acid) to facilitate controlled release and absorption through the oral mucosa. It is primarily used in gum and lozenge forms for nicotine replacement therapy (NRT) to aid smoking cessation. The delivery system maximizes the amount of nicotine absorbed by the mouth—about 80–90% of released nicotine—helping reduce withdrawal symptoms and cravings associated with quitting smoking. Common side effects include bad taste, nausea, dyspepsia, stomatitis, dizziness, dry mouth or throat soreness[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotine polacrilex.